Skip to main content

Personal Genetics - Code of Practice

This blog is about personal genetics and disease prevention - the EUROGENE eTEN project was set up and funded by the EU to establish the infrastructure to deliver personal genetics services via practitioner or direct to consumer.

The aim of the blog will be to report on progress of the project and comment on relevant research / developments in related areas. One of the tasks of the project was a review of the European regulatory framework - this has been completed and will be summarised in a later blog (the full review has also been submitted for publication.

The main finding is the absence of formal regulations in place now and the probability that this unclear situation will not change for some time. Meanwhile personal genetics services roar ahead, with prices falling and genome coverage increasing. Our opinion is that we should follow and promote the Industry Code of Practice proposed by the UK Human Genetics Commission (HGC). This code was developed by academics, regulators, industry members and medical stakeholders to cover all aspects including testing, marketing, customer support, quality of information. In the absence of formal regulation we welcome the code and feel very strongly that the customer (both the practitioner and the end-user) should be fully informed about all aspects of the genetic testing services and all information should be easily available online. The first thing that any potential user of a genetic test, is full disclosure and transparency and we also feel that all companies should protect both the industry and consumers by following the HGC guidelines

“Common Framework of Principles for direct-to-consumer genetic testing services”

Claims must be accurate (promotional and technical), evidence transparent
• Genetic variants tested must have been clinically validated
• Risk assessments must use accepted methods and be transparent
• Clarity on privacy and use of customer’s DNA
• Full and clear information for the customer to understand the test including accuracy and limitations
• Recommendations to purchase follow-on products (e.g. supplements) must be fully and transparently supported by scientific evidence
• For some tests professional genetic and medical help should be available if needed
• Tests should not be supplied DTC to adults unable to provide informed consent

Comments

  1. Greetings! Lot of information within this post! It is the little changes that produce the most significant changes. I found very important information on human genome testing. Thanks for sharing!

    ReplyDelete

Post a Comment

Popular posts from this blog

Genetic testing and potential harm: DTC or trust me I’m a doctor?

Recently at a couple of conferences ( European Human Genetics conference and Consumer Genetics Conf ) there have been various speakers questioning DTC genetics and calling for all health related personal genetics to be delivered through medical practitioners. I argued in the past that unregulated tests delivered through practitioners actually have the potential for more harm, not less. By coincidence last week some discrepancies in a DTC and a via MD test were pointed out to me – and they seem topical. Breast feeding has many benefits one of which appears to be increased IQ scores – however not all studies agree, some indicating that results may be confounded by maternal intelligence (see Wikipedia ). Sometimes inconsistencies in associating an action with an outcome can be resolved by looking at genetic variation (which tends to increase the error bars when not accounted for). So in 2007 some headlines were made when a study was published by Caspi’s group ( PNAS, open access )

FDA – Personal Genetics: Is it safe? It’s a marathon, man…

It’s nearly 10 years now and still there is no clarity about the position of personal genetics in the regulatory framework. Maybe that’s going to change soon with the FDA activity and the recently published HGC Principles . It would be good to get it settled one way or another, the uncertainly doesn’t help anyone except those who exploit it to exploit the gullible. Some elements: DTC vs. DTMD (via physician) – I will argue that DTMD is actually higher risk and needs closer scrutiny Is it medicine? I think this question is a waste of time, it will not be resolved, the definition is too broad, medicine is practised everywhere by everyone - if I take my son’s temperature, put a plaster on a cut or administer medication I am practising medicine. What is the FDA duty bound to do and what will they decide? No regulation – more or less the current situation Tight regulation – medium/high risk requiring pre market approval (PMA) Somewhere in between

Personal Genetics has a Family History of getting beaten up

Over the last few days personal genetics has come in for a bit of a bashing, first it was knocked out by family history then it was clearly nailed into the coffin by traditional risk factors . Also have a look at Genesherpa’s blog for some more putting the boot in here and here . Update: Nov 12th, here is the 23andMe blog on the subject But what is behind the hype and the headlines? In this post I will look at family history and deal with EGAPP in the next. The latest attack was sparked by a press release of some work presented at the ASHG. We don’t know too much because all we have is an abstract and a video but we have enough. FH was compared to the Navigenics genetic profile (PGS). From the abstract “None of the 3 hereditary prostate cancer subjects were assessed as high risk on PGS. Based on FHRA, 10 subjects had hereditary breast cancer risk and PGS only identified 1 as high risk (K=0.12). None of the 9 hereditary colon cancer subjects were high risk on PGS.”